Clinical trial
A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat…
NCT00369889 · Indiana University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00369889 |
|---|---|
| Title | A Study to Test the Safety and Efficacy of Erlotinib Plus Bevacizumab to Treat Advanced Thymoma and Thymic Cancer |
| Official title | A Phase II Study of Erlotinib Plus Bevacizumab in the Treatment of Advanced Thymoma and Thymic Carcinoma |
| Lead sponsor | Indiana University School of Medicine, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Thymic Cancer, Thymoma |
| Intervention type | Drug |
| Interventions | bevacizumab, Erlotinib |
| Enrollment | 18 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Aug 30, 2006 |
| Last update posted | Jun 3, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: